Personalized Cancer Chemotherapy

Personalized Cancer Chemotherapy separately describes and addresses "individualized cancer chemotherapy" (ICC) strategies new and old, to provide readers with new insights into their characteristics and techniques, as well as key debates and future trends in this area. The book devotes chapters to drug sensitivity testing, cancer biomarkers and bioinformatics detection, pharmacogenetics, individualized antimetastatic therapy, drug combinations, assistant chemotherapy, and cost-effectiveness considerations. A major obstacle to controlling cancer growth and metastases in patients is the inappropriate use of anticancer and antimetastatic drugs. Researchers and clinicians are now beginning to focus on ICC also called "personalized cancer chemotherapy" (PCC), to improve therapeutic quality and outcomes by selecting and prescribing the most appropriate and effective drugs. Using genetic, molecular, and bioinformatics data and modern experimental techniques, known tumor genes can be detected more easily than ever before; the average speed of genetic sequencing has increased 15,000 to 50,000 times since the Human Geonme Project was completed. This book will help readers understand the pros and cons of each individualized cancer chemotherapy strategy from different angles so as to make good judgments and predictions of drug responses and clinical outcomes. Explores the central components of cancer treatment Investigates new developments in cancer treatment Discusses the many strategies of individualized cancer chemotherapy

Customized Cancer Treatment is the first book for the layperson on chemosensitivity testing. This is a laboratory procedure by which patients and their doctors can discover which drugs are mostly like to work for them and which to avoid. Chemosensitivity testing is very effective at finding the best drugs for each individual. It is a form of personalized treatment. According to Dr. Robert Nagourney, No cancer patient should begin treatment without first reading this book.

Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests. The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first "site-agnostic" drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic "signatures" that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment.

This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.

Personalized cancer medicine studies human genes in different types of cancers. This field of medicine is helpful in designing more efficient treatments by utilising genetic information for developing different tests for cancer and the ways for preventing it. Standard cancer treatments are divided into four categories, which include chemotherapy, surgery, immunotherapy and radiation therapy. The patient's active participation is crucial to enhance the effectiveness of personalized medicines. It has fewer side effects than other forms of treatment, as it is designed to be more precise. A personalized treatment will not target the healthy cells and can have greater impact on cancer cells. Targeted therapy is one of the examples of personalized cancer medicine, which can be used to treat brain cancer, cervical cancer, breast cancer, liver cancer and pancreatic cancer. This book explores all the important principles of personalized cancer medicine. It presents researches and studies performed by experts across the globe. This book is appropriate for students seeking detailed information in this area of medicine as well as for experts.

For this volume of Advances in Pharmacology we have brought together some of the foremost basic science and clinical researchers to discuss some of the new frontiers in the development of targeted cancer therapy. Although still in its formative stages, the development of targeted cancer therapies has already shown incredible promise in a limited number of cancer types. As basic cancer research and drug development continues, we expect this number to grow and more patients to benefit from these exciting advances. Through better patient selection and novel strategies to manage resistance, a future can be envisaged in which cancer can be reduced to the level of a chronic, manageable disease. Brought together some of the foremost basic science and clinical researchers Part of the renowned Advances in Pharmacology Serial Discussion of some of the new frontiers in the development of targeted cancer therapy

The role of molecular genetics in the treatment of malignancy continues to grow at an astonishing rate. Today’s subspecialized multidisciplinary approach to oncology has incorporated advances in targeted molecular therapy, prognosis, risk assessment, and prevention—all based at least in part on molecular diagnostics and imaging. Inside this cutting-edge resource, readers will explore broad, comprehensive perspectives on the current trends in molecular diagnosis of cancer and personalized cancer medicine. Authoritative discussions share insights from noted experts in cancer research, clinical trials, molecular diagnostics, personalized therapy, bioinformatics, and federal regulations. From the basic mechanisms of carcinogenesis to the most advanced molecular screening, staging, and treatment technologies, readers will discover clear and straightforward discussions directly relevant to patient diagnosis and care.